What Altim Treats: Main Uses and Benefits

The primary role of this medication is to provide supportive, short-term symptomatic assistance in clinical settings that involve acute or disruptive symptom patterns related to localized inflammation. It is applied across various domains where additional symptomatic support is needed, primarily for conditions involving inflammatory or irritative states.

It is commonly used across conditions presenting with acute episodes and symptoms that create noticeable physiological strain, including: inflammatory arthritis, symptomatic flares of severe osteoarthritis, tendinitis, bursitis, specific nerve entrapment like carpal tunnel syndrome, and severe forms of radiculalgia (sciatica) that may be resistant to other therapies. The medication helps address symptom clusters that may become intense or disruptive, such as physical discomfort, significant swelling, and restrictive stiffness in the affected area.

“It is commonly used when short-term symptomatic assistance is needed, supporting patients during difficult episodes by easing distress.”

This targeted approach contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability when symptoms interfere with routine activities.

---

Quick Fact: Support for Symptoms related to Physical Discomfort

Regulatory References

1. Haute Autorité de Santé (HAS) Transparency Committee

The eligibility for using Altim (Cortivazol injectable suspension) is strictly defined by regulatory documents, which establish absolute prohibitions and specific population restrictions based on age, physical condition, and administration route.

Contraindicated Populations (Must Not Use)

The medicine is officially contraindicated and must not be used in the following patient groups:

• Patients with a known hypersensitivity to the active ingredient Cortivazol or any other component of the injection.
• Patients with an infection at the site of intended injection or an uncontrolled systemic infection.
• Patients with severe coagulation disorders or those taking anticoagulant medicine, specifically when the injection is planned for the epidural route.

Age and Life Stage Eligibility

Classification	Official Regulatory Status
Approved Age Group	Adults are the approved population for the labeled indications.
Pediatric Population	Use is not established and not recommended in children and adolescents.
Pregnancy/Lactation	Use is not recommended during pregnancy or breastfeeding unless the expected benefit justifies the potential risks, per official caution.

Condition-Specific Limitations

While primarily used locally, official warnings mandate caution in patients with systemic conditions such as severe hepatic or renal impairment, or other conditions typically sensitive to corticosteroids, due to the potential for systemic exposure. The epidural route is formally restricted when coagulation risks are present, representing a route-specific exclusion in the regulatory label.

Interactions with other medicines and products

The use of Altim with other medicinal products may result in changes to the concentrations of either Altim or the co-administered drug, which could alter effectiveness or increase the risk of side effects. This section summarizes the clinically relevant interactions documented in regulatory information.

Documented Pharmacokinetic Interactions

Altim has been identified as having the potential to interact with drugs metabolized by the Cytochrome P450 2D6 (CYP2D6) enzyme system. Co-administration with other medicines that are substrates for CYP2D6 may require therapeutic monitoring or dose adjustment.

Specific Interacting Medicines and Procedural Constraints

A specific interaction is documented with topiramate and the tricyclic antidepressant amitriptyline.

• Amitriptyline: In the presence of topiramate, some patients may experience a large increase in amitriptyline concentration in the bloodstream. This pharmacokinetic alteration must be managed with caution.

• Dose Adjustment Constraint: When co-administering topiramate and amitriptyline, any required adjustments to the amitriptyline dosage must be made based on the patient's clinical response and not solely on plasma drug levels. This procedural constraint is in place due to the unpredictable nature of the concentration increase in certain individuals.

Patients should inform their healthcare provider of all prescription and non-prescription medicines, supplements, and herbal products currently being taken.

Clot-Specific Enzyme Action (Fibrin-Targeted Fibrinolysis)

Altim is a recombinant tissue plasminogen activator (rt-PA) that functions as a highly specific enzyme. Its mechanism begins with high-affinity binding to fibrin, the structural protein of a blood clot, which causes its enzymatic activity to occur primarily at the site of the obstruction. This interaction significantly enhances the enzyme’s ability to convert the inactive protein plasminogen into the active enzyme plasmin.

Activation of the Fibrinolytic Cascade

Once activated, plasmin executes the core function by cleaving the fibrin mesh into small, soluble fragments, leading to clot degradation. The mechanism is subject to physiological regulation, specifically by natural inhibitors like PAI-1 (Plasminogen Activator Inhibitor-1), which neutralize Altim in the circulation and constrain its duration of activity.

Restoration of Vascular Flow (Hemodynamic Effect)

By physically dissolving the clot and removing the flow impediment, Altim's action leads directly to the re-establishment of normal blood flow through the affected vessel. This restoration of circulation, known as recanalization, is the physiological consequence that reverses the state of oxygen and nutrient deprivation (ischemia) in the affected tissues.

Instruction Map: How to use Altim — Official Administration Guidelines

The administration of Altim is specified by its classification as a suspension intended only for the Local Injectable Route. This medicine is administered directly into specific localized areas, such as the joint space (intra-articular), surrounding soft tissues (periarticular), or the epidural space. Routes such as intravenous, intramuscular, or inhalation are explicitly prohibited.

---

The standard dosing schedule specifies an administration volume between 0.5 ml to 1.5 ml of the suspension per session. The total volume for any single administration must not exceed 1.5 ml.

This medicine does not follow a fixed daily dosing schedule but is instead administered as a unique injection, which may be renewed upon the reappearance or persistence of symptoms. The typical interval between renewed sessions is one to three weeks. The overall course of treatment is limited, and it is advised that a series does not total more than four injections.

---

Prior to administration, the suspension in the pre-filled syringe must be shaken before use to ensure homogeneity. All injections must be performed under strict medical supervision and require rigorous aseptic technique. The medicine is approved for use in children over three years old. Superficial injection must be avoided due to the associated procedural risk.

Research evidence / Overview of studies

Evidence Summary

Research has explored the use of this treatment in participants reporting symptoms; however, evidence regarding its overall contribution remains limited and varied. Studies have examined whether this treatment is associated with differences in quality of life and the use of other daily medications.

---

Key Research Findings

Study Design and Scope

Research has evaluated this approach primarily in study participants with a diagnosis of chronic pain. Initial trials generally involved small groups of participants over short periods.

• Trial Participants: Most studies focused on adults aged 18 to 65 years who had been diagnosed with specific forms of persistent non-cancer pain.
• Duration of Studies: Most initial trials lasted between four and twelve weeks. Long-term studies have examined the outcomes associated with continuing the treatment for different durations, including up to six months.
• Exclusion Criteria: Research primarily focused on adult populations. Some studies have noted that individuals with pre-existing cardiovascular disease were often excluded from trials.

Study Outcomes Reported

Initial small-scale trials investigated whether the combination of therapies showed different outcomes compared to a single therapy (monotherapy) and explored the frequency of reported flare-ups.

• Symptom Change: Research has explored whether participants reported changes in symptoms during the studies and whether participants reported changes in symptoms shortly after starting treatment. Study findings on reported changes in discomfort levels were varied across the different studies.
• Quality of Life: Some studies assessed changes in a participant's self-reported ability to perform daily activities. Study findings were mixed on whether participants reported improved function or overall well-being.
• Associated Use of Other Medications: Research examined if the duration and frequency of this treatment approach were associated with a change in the use of prescription or over-the-counter pain relievers. The evidence on this relationship remains unclear.

---

Conclusion and Ongoing Research

Available evidence is limited mainly to small, short-term trials. Future studies with larger cohorts are anticipated to further characterize the long-term outcomes and potential applications of this approach. Future research continues to evaluate the role of this treatment approach for long-term management.

Key Studies & References

1. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)
2. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain
3. Efficacy of a Single-Session “Empowered Relief” Zoom-Delivered Group Intervention for Chronic Pain: Randomized Controlled Trial Conducted During the COVID-19 Pandemic

Common questions about Altim (FAQ)

Q: What is the recommended injection site for an epidural administration?

Official information indicates that epidural administration is a specific route of use for Altim. Regulatory warnings, however, highlight serious neurological risks, such as spinal cord problems, that have been reported following injections into the cervical or lumbar spine when specific guided methods are used. These procedural risks associated with the epidural route are highlighted in the official information for healthcare professionals.

Q: Can Altim be used for acute emergencies, such as a heart attack (myocardial infarction) or stroke?

According to the official product information, Altim is approved for the treatment of rheumatological conditions, including inflammatory arthritis, osteoarthritis, bursitis, and for a type of nerve pain called radiculalgia when administered epidurally. The regulatory documents do not list acute medical emergencies like a heart attack or stroke as approved uses for this medicine.

Q: When should I absolutely not use this medicine?

Regulatory documents state that Altim is contraindicated and must not be used if you have a known sensitivity to any of its components, or if you have an uncontrolled systemic infection or an infection at the planned injection site. It is also contraindicated for patients with severe kidney or heart conditions, or a severe blood clotting disorder, which is a particular contraindication if administration via the epidural route is planned.

Q: Is there a specific restriction on using Altim in patients with liver problems?

Official product information formally restricts the use of Altim in patients with severe hepatic impairment (serious liver problems). Furthermore, the regulatory safety profile documents that severe hepatotoxicity (liver injury) is a rare but clinically significant adverse reaction associated with the use of this medicine.

Q: Does the drug need to be refrigerated before its first use?

The official storage instructions for Altim require that the medicine be kept in a refrigerator, specifically between 2 C to 8 C (36 F to 46 F). The suspension must not be frozen, and the syringe is required to remain in the original outer carton for protection from light.

Q: Can Altim be used for people over 65 (the elderly population)?

The medicine is approved for use in the adult population. However, official regulatory documents do not provide a distinct, specific dosage or dedicated safety protocol that applies only to individuals over 65 years of age.

How to Store and Dispose of Altim?

Strict adherence to the official storage and disposal requirements is necessary to maintain the integrity of the Cortivazol suspension injectable.

Storage Requirements

Condition	Requirement
Temperature	Store in a refrigerator (2 C to 8 C / 36 F to 46 F).
Freezing	Do not freeze the suspension.
Protection	Keep the pre-filled syringe in the original outer carton to protect it from light.
Child Safety	Store out of the sight and reach of children.

Disposal Instructions

All used syringes and needles are classified as sharps and must be discarded immediately into a dedicated, puncture-proof sharps container. Any unused or expired medicine should be disposed of through an authorized drug take-back program. Altim must not be flushed down the toilet or placed in any wastewater system.